World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
35152
World Ranking
6608
National Ranking
639

Overview

Martin J. S. Dyer is affiliated with the University of Leicester in the United Kingdom. Their research is primarily situated within the field of Medicine, with a substantial focus on genetics, pathology and forensic medicine, immunology, oncology, and hematology. Their work spans across several subfields, reflecting a multidisciplinary approach to medical science.

Their major research areas include chronic lymphocytic leukemia, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, CAR-T cell therapy, chronic myeloid leukemia treatments, viral-associated cancers, and acute myeloid leukemia research.

Frequently publishing in high-impact venues, Dyer's work appears often in Blood Advances, Leukemia, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. These journals are well known for disseminating research related to blood cancers and hematological disorders.

Recent notable papers authored or coauthored by Martin J. S. Dyer include:

  • The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy, 2025, Signal Transduction and Targeted Therapy
  • Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia, 2020, Clinical Cancer Research
  • Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies, 2021, Leukemia
  • Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen, 2022, Blood Advances
  • Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study, 2023, HemaSphere

Martin J. S. Dyer collaborates frequently with other researchers in the field. Prominent coauthors include Sandrine Jayne, Harriet S. Walter, Victoria M. Smith, Meike Vogler, and Simon Rule. These collaborations contribute to a substantial number of publications and ongoing research projects.

Best Publications

  • Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

    Ekkehard Mössner;Peter Brünker;Samuel Moser;Ursula Püntener

  • Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types

    Tony G. Willis;Dalal M. Jadayel;Ming-Qing Du;Huaizheng Peng

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

    Nathalie A. Johnson;Kerry J. Savage;Olga Ludkovski;Susana Ben-Neriah

  • REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

    G. Hale;M.R. Clark;R. Marcus;G. Winter

  • Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

    Cristian Bellodi;Maria Rosa Lidonnici;Ashley Hamilton;G. Vignir Helgason

  • Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

    A. Österborg;M. J. S. Dyer;D. Bunjes;G. A. Pangalis

  • Deregulated expression of cytokine receptor gene, CRLF2 , is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

    Lisa J. Russell;Melania Capasso;Inga Vater;Takashi Akasaka

  • Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.

    Martin J.S. Dyer;Geoffrey Hale;Frank G.J. Hayhoe;Herman Waldmann

  • Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

    Meike Vogler;David Dinsdale;Martin J. S. Dyer;Gerald M. Cohen

  • Ultrastructural localization of bcl-2 protein.

    P. Monaghan;D. Robertson;T. A. S. Amos;M. J. S. Dyer

  • A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

    Maria Chiara Di Bernardo;Dalemari Crowther-Swanepoel;Peter Broderick;Emily Webb

  • Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

    Meike Vogler;Michael Butterworth;Aneela Majid;Renata J. Walewska

  • The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.

    Tony G. Willis;Martin J. S. Dyer

  • The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

    Victoria J. Weston;Ceri E. Oldreive;Anna Skowronska;David G. Oscier

  • High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

    Claire E. Dearden;Estella Matutes;Bruno Cazin;Geir E. Tjønnfjord

  • The CAMPATH‐1 antigen (CDw52)

    Geoffrey Hale;Meng-Q. Xia;Helen P Tighe;Martin J. S. Dyer

  • Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.

    Lia Ginaldi;T Massimo De Martinis;Estella Matutes;Nahla Farahat

  • The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.

    Ed Satterwhite;Takashi Sonoki;Tony G. Willis;Lana Harder

  • Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells (vol 119, pg 1109, 2009)

    C Bellodi;Lidonnici;A Hamilton;GV Helgason

Frequent Co-Authors

Reiner Siebert
Reiner Siebert University of Ulm
Daniel Catovsky
Daniel Catovsky Institute of Cancer Research
Gerald M. Cohen
Gerald M. Cohen University of Liverpool
David Oscier
David Oscier Royal Bournemouth Hospital
Estella Matutes
Estella Matutes University of Barcelona
Peter Hillmen
Peter Hillmen St James's University Hospital
Stefan Gesk
Stefan Gesk Kiel University
Richard S. Houlston
Richard S. Houlston Institute of Cancer Research
José I. Martín-Subero
José I. Martín-Subero University of Barcelona
Anders Österborg
Anders Österborg Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education options in healthcare can open diverse career pathways beyond traditional medical school. Many students pursue advanced nursing roles, and flexible programs like dnp programs without dissertation let experienced nurses earn a Doctor of Nursing Practice without extensive research commitments.

If you’re seeking a quicker entry into the healthcare field, lpn online programs allow aspiring practical nurses to begin their careers in as little as a year. Those interested in mental health can specialize through the shortest pmhnp program, earning an MSN focused on psychiatric and mental health nursing at an accelerated pace.

For those drawn to leadership or administrative roles within hospitals and clinics, an online health management degree provides essential management skills at a potentially lower cost than traditional, on-campus programs.

Each of these online degree options—ranging from practical nursing to healthcare administration—can help students build a rewarding career in medicine and allied health professions, often with greater flexibility and affordability.

Best Scientists Citing Martin J. S. Dyer

Trending Scientists

Recently Published Articles